Annual Reports in Medicinal Chemistry

<ol> <li>A Personal Essay: My Experiences in the Pharmaceutical Industry</li> <li>Adventures in Medicinal Chemistry - A Career in Drug Discovery</li> <li>Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABA_A and NMDA Receptors</li> <li>Development of LRRK2 Kinase Inhibitors for Parkinson’s Disease</li> <li>Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders</li> <li>Small Molecule Modulators of GPR40 (FFA1)</li> <li>Recent Advances in the Development of P2Y₁₂ Receptor Antagonists as Antiplatelet Agents</li> <li>Current Approaches to the Treatment of Atrial Fibrillation</li> <li>Advances in the Discovery of Small Molecule IRAK4 Inhibitors</li> <li>H₄ Receptor Antagonists and Their Potential Therapeutic Applications</li> <li>Urate Crystal Deposition Disease and Gout - New Therapies for an Old Problem</li> <li>p53 - MDM2 and MDMX Antagonists</li> <li>Modulators of Atypical Protein Kinase C as Anticancer Agents</li> <li>Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis</li> <li>Nucleosides and Nucleotides for the Treatment of Viral Diseases</li> <li>Advances in Inhibitors of Penicillin Binding Proteins and β-lactamases as Antibacterial Agents</li> <li>Tumor Microenvironment as Target in Cancer Therapy</li> <li>Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)</li> <li>Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications</li> <li>Disease Modifying Agents for the Treatment of Cystic Fibrosis</li> <li>Advancements in Stapled Peptide Drug Discovery and Development</li> <li>Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development</li> <li>Case History: Forxiga^TM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes</li> <li>Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation</li> <li>Case History: Xeljanz^TM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis</li> <li>New Chemical Entities Entering Phase III Trials in 2013</li> <li>To Market, To Market – 2013</li></ol>